Adjunct intra-arterial alteplase after thrombectomy improved 90-day functional recovery in LVO stroke (57.5% vs 42.5%). Headache occurs in 46% of hemorrhagic stroke patients; only 21.8% of stroke/TBI patients receive inpatient rehab.
In TRIDENT, GMRx2 reduced recurrent stroke risk by 39% after intracerebral hemorrhage. LT3001 was safe in phase 2 acute ischemic stroke trials, supporting a global phase 3.
The phase 3 OCEANIC-STROKE trial of 12,327 patients showed asundexian, an oral Factor XIa inhibitor, reduced ischemic stroke recurrence by 26% when added to standard antiplatelet therapy, with no increase in major bleeding events.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07801599 |
Huayu Jiedu Formula (FTFY-919) Granules Versus Traditional Decoction for Acute Hypertensive Intracerebral Hemorrhage |
NOT_YET_RECRUITING | PHASE3 |
| NCT06368648 |
CoMind Early Feasibility Study |
RECRUITING | |
| NCT05491980 |
Florida Cerebrovascular Disease Biorepository and Genomics Center |
ACTIVE_NOT_RECRUITING | |
| NCT04760717 |
Regulating Blood Pressure During Recovery From Intracerebral Hemorrhage and Ischemic Stroke |
ACTIVE_NOT_RECRUITING | PHASE2 |
